Cargando…
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the so-called...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360015/ https://www.ncbi.nlm.nih.gov/pubmed/32699984 http://dx.doi.org/10.1007/s40487-019-00098-w |